TNNI3 and COVID-19: In the model that included age, sex, and comorbidity effects, critical patients with high hs-cTnI level were 2.637 times more likely to die than those with low levels (95% CI,1.058-6.570, p = 0.037), which indicates that hs-cTnI levels may be useful in assessing mortality risk in critically ill patients with COVID-19.